Publications
Detailed Information
Survival improvement with combined radio-chemotherapy in the primary central nervous system lymphomas
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wu, Hong Gyun | - |
dc.contributor.author | Kim, Il Han | - |
dc.contributor.author | Ha, Sung Whan | - |
dc.contributor.author | Park, Charn Il | - |
dc.contributor.author | Bang, Young Joo | - |
dc.contributor.author | Huh, Dae Seok | - |
dc.date.accessioned | 2021-01-31T11:04:08Z | - |
dc.date.available | 2021-01-31T11:04:08Z | - |
dc.date.created | 2020-12-23 | - |
dc.date.issued | 1999-10 | - |
dc.identifier.citation | Journal of Korean Medical Science, Vol.14 No.5, pp.565-570 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.other | 119596 | - |
dc.identifier.uri | https://hdl.handle.net/10371/172999 | - |
dc.description.abstract | The benefits of radio-chemotherapy in HIV-negative primary central nervous system (CNS) lymphomas were analyzed in 40 patients, who received radiotherapy to the brain or craniospinal axis with the total dose of 4460-5940 cGy to the primary tumor. Radiotherapy was followed by systemic chemotherapy, mainly with the cyclophospharmide, doxorubicin, vincristine and prednisolone (CHOP) regimen, in 16 of the patients. Follow-up ranged from four to 95 months with a median of 15 months. The relapse rate was 72.5%, and 83% of the relapses occurred within the radiation field. Median survival was 19 months and the two-year survival rate was 41%, Survival was significantly influenced by treatment method and radiation dose when measured by univariate analysis; median survival and the two-year survival rate was 29 months and 63% after radio-chemotherapy, while 13.5 month and 29% after radiotherapy alone (p=0.027), and 22 months and 49% with doses of 50 Gy or more, but 12.5 months and 13% with doses less than 50 Gy (p=0.009), However, statistical significance was lost in multivariate analysis. These results might suggest the short-term efficacy of radio-chemotherapy, however, cautious observation is needed to confirm long-term effects. | - |
dc.language | 영어 | - |
dc.publisher | 대한의학회 | - |
dc.title | Survival improvement with combined radio-chemotherapy in the primary central nervous system lymphomas | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.identifier.doi | 10.3346/jkms.1999.14.5.565 | - |
dc.citation.journaltitle | Journal of Korean Medical Science | - |
dc.identifier.wosid | 000083240900015 | - |
dc.identifier.scopusid | 2-s2.0-0033203410 | - |
dc.citation.endpage | 570 | - |
dc.citation.number | 5 | - |
dc.citation.startpage | 565 | - |
dc.citation.volume | 14 | - |
dc.identifier.sci | 000083240900015 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Wu, Hong Gyun | - |
dc.contributor.affiliatedAuthor | Kim, Il Han | - |
dc.contributor.affiliatedAuthor | Ha, Sung Whan | - |
dc.contributor.affiliatedAuthor | Park, Charn Il | - |
dc.contributor.affiliatedAuthor | Bang, Young Joo | - |
dc.contributor.affiliatedAuthor | Huh, Dae Seok | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | NON-HODGKINS-LYMPHOMA | - |
dc.subject.keywordPlus | PRIMARY MALIGNANT-LYMPHOMA | - |
dc.subject.keywordPlus | RADIATION-THERAPY | - |
dc.subject.keywordPlus | BRAIN | - |
dc.subject.keywordPlus | TOMOGRAPHY | - |
dc.subject.keywordAuthor | radiotherapy | - |
dc.subject.keywordAuthor | drug therapy | - |
dc.subject.keywordAuthor | lymphoma | - |
dc.subject.keywordAuthor | central nervous system | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.